WARRENDALE, Pa., July 17 /PRNewswire/ -- MEDRAD, INC.'s P3T(TM) Cardiac CT application was selected to be showcased at the Premier healthcare alliance’s first annual Innovation Celebration, an event designed to recognize healthcare suppliers that are committed to improving patient outcomes through product innovation. Premier contracts with over 800 suppliers, and the P3T(TM) Cardiac was one of only 24 products showcased at the event.
P3T Cardiac software uses a patented algorithmic model to automate administration of individualized contrast injection protocols according to patient, procedure and prescribed physician parameters. Clinicians consistently provide the right amount of contrast at the right rate of delivery for each individual patient - enhancing image quality while maintaining efficient workflow.
“We are very proud to be recognized by Premier for our advances in personalizing CT contrast-enhanced imaging,” says Anthony Cinalli, executive director, MEDRAD Radiology Marketing. “Each new P3T application we release furthers our commitment to outcome-based innovation, and enables more patients to receive the benefits personalized imaging delivers.”
For more information, please visit: http://www.premierinc.com/about/events-education/breakthroughs/2009/supplier/innovation-celebration.jsp
About MEDRAD, Inc.
MEDRAD, Inc. develops, markets and services medical devices used to diagnose and treat disease. Its product offerings include fluid injection systems for radiology and cardiology, endovascular devices for the safe treatment of cardiovascular disease, magnetic resonance-compatible accessories and equipment services. The company’s world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is a business of Bayer Medical Care. More company information is available at www.medrad.com.
Forward-looking statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
(1.) Presented at Society of Thoracic Radiology (2008) Poster Session; Christopher R. Deible MD, PhD
Photo: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGO
http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.comMEDRAD, Inc.
